JPWO2020047352A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047352A5 JPWO2020047352A5 JP2021510984A JP2021510984A JPWO2020047352A5 JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5
- Authority
- JP
- Japan
- Prior art keywords
- hae
- composition
- antibody
- treatment period
- prior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019860 Hereditary angioedema Diseases 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 25
- 102000004965 antibodies Human genes 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 16
- 230000035492 administration Effects 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 108010005563 Complement C1 Inhibitor Protein Proteins 0.000 claims 3
- 102100009270 SERPING1 Human genes 0.000 claims 3
- 229940009550 C1 esterase inhibitor Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 229940068968 Polysorbate 80 Drugs 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims 1
- 229940030486 ANDROGENS Drugs 0.000 claims 1
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims 1
- VBGWSQKGUZHFPS-VGMMZINCSA-N Kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 claims 1
- 102000003827 Plasma kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma kallikrein Proteins 0.000 claims 1
- 239000000504 antifibrinolytic agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000003152 bradykinin antagonist Substances 0.000 claims 1
- 229960000766 danazol Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001174 ecallantide Drugs 0.000 claims 1
- 108010011867 ecallantide Proteins 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229960001062 icatibant Drugs 0.000 claims 1
- RNFSRGBKGWQTPO-SKXRKSCCSA-N icatibant Chemical compound NC(=N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C[C@@H](O)C1 RNFSRGBKGWQTPO-SKXRKSCCSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 229960000401 tranexamic acid Drugs 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024094996A JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725216P | 2018-08-30 | 2018-08-30 | |
US62/725,216 | 2018-08-30 | ||
US201962808612P | 2019-02-21 | 2019-02-21 | |
US62/808,612 | 2019-02-21 | ||
PCT/US2019/048961 WO2020047352A1 (fr) | 2018-08-30 | 2019-08-30 | Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-œdème héréditaire |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024094996A Division JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535161A JP2021535161A (ja) | 2021-12-16 |
JPWO2020047352A5 true JPWO2020047352A5 (fr) | 2022-09-05 |
Family
ID=67953889
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510984A Pending JP2021535161A (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20200109214A1 (fr) |
EP (1) | EP3843840A1 (fr) |
JP (2) | JP2021535161A (fr) |
KR (1) | KR20210053928A (fr) |
CN (1) | CN113056304A (fr) |
AU (1) | AU2019328324A1 (fr) |
BR (1) | BR112021003789A2 (fr) |
CA (1) | CA3110689A1 (fr) |
IL (1) | IL281063A (fr) |
MA (1) | MA53490A (fr) |
MX (1) | MX2021002349A (fr) |
WO (1) | WO2020047352A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
CA2906624A1 (fr) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anticorps anti-kallicreine plasmatique |
WO2015148790A1 (fr) | 2014-03-27 | 2015-10-01 | Dyax Corp. | Compositions et procédés pour le traitement de l'oedème maculaire diabétique |
NZ744233A (en) | 2015-12-11 | 2023-11-24 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
JP2023510854A (ja) * | 2020-01-13 | 2023-03-15 | 武田薬品工業株式会社 | 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
JP3805785B2 (ja) | 1994-01-11 | 2006-08-09 | ダイアックス コープ. | カリクレイン阻害クニッツドメイン蛋白質およびその相同体 |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO2003103475A2 (fr) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention et reduction de la perte sanguine |
KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
CA2906624A1 (fr) * | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anticorps anti-kallicreine plasmatique |
WO2015148790A1 (fr) * | 2014-03-27 | 2015-10-01 | Dyax Corp. | Compositions et procédés pour le traitement de l'oedème maculaire diabétique |
EP3286226A4 (fr) * | 2015-03-30 | 2018-12-05 | Dyax Corp. | Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire |
NZ744233A (en) * | 2015-12-11 | 2023-11-24 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2017106679A1 (fr) * | 2015-12-18 | 2017-06-22 | Graco Minnesota Inc. | Installation de soufflet et procédé de maintien |
-
2019
- 2019-08-30 CN CN201980072190.9A patent/CN113056304A/zh active Pending
- 2019-08-30 KR KR1020217009365A patent/KR20210053928A/ko active Search and Examination
- 2019-08-30 AU AU2019328324A patent/AU2019328324A1/en active Pending
- 2019-08-30 BR BR112021003789-6A patent/BR112021003789A2/pt unknown
- 2019-08-30 WO PCT/US2019/048961 patent/WO2020047352A1/fr unknown
- 2019-08-30 JP JP2021510984A patent/JP2021535161A/ja active Pending
- 2019-08-30 MX MX2021002349A patent/MX2021002349A/es unknown
- 2019-08-30 EP EP19768977.1A patent/EP3843840A1/fr active Pending
- 2019-08-30 MA MA053490A patent/MA53490A/fr unknown
- 2019-08-30 CA CA3110689A patent/CA3110689A1/fr active Pending
- 2019-08-30 US US16/556,524 patent/US20200109214A1/en not_active Abandoned
-
2021
- 2021-02-23 IL IL281063A patent/IL281063A/en unknown
-
2022
- 2022-05-16 US US17/745,770 patent/US20230104754A1/en active Pending
-
2024
- 2024-06-12 JP JP2024094996A patent/JP2024113183A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022033868A5 (fr) | ||
JP2019501886A5 (fr) | ||
US20240052058A1 (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
Gurfinkel et al. | Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study | |
JP2020002171A5 (fr) | ||
Weitz | Factor XI and factor XII as targets for new anticoagulants | |
JP2018514510A5 (fr) | ||
JPWO2020047352A5 (fr) | ||
JPWO2020186132A5 (fr) | ||
UA127588C2 (uk) | Способи застосування та композиції, які містять дулаглутид | |
KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
IL296872A (en) | Preventive treatment for migraine | |
AU2016221627A1 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
JPWO2021146160A5 (fr) | ||
RU2021129732A (ru) | Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека | |
US20210338766A1 (en) | Methods of treating multiple myeloma | |
JPWO2019215701A5 (fr) | ||
WO2021255438A1 (fr) | Combinaison de dexaméthasone et d'un antagoniste du récepteur des minéralocorticoïdes destinée à être utilisée dans le traitement du syndrome de détresse respiratoire aiguë | |
EP4069737A2 (fr) | Procédés de traitement de lichen plan à l'aide d'antagonistes de l'interleukine 17 (il-17) | |
CN118556078A (zh) | 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 | |
WO2021108862A1 (fr) | Utilisation d'un anticorps anti-facteur xii pour le traitement ou la prévention de l'oedème de quincke héréditaire | |
RU2022101306A (ru) | Схема введения доз и виды комбинированной терапии для полиспецифических антител, нацеленных на антиген созревания в-клеток | |
Reisch et al. | Use of Angiotensin-Converting Enzyme Inhibitors for the Preservation of Kidney Function | |
MX2011000673A (es) | Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico. | |
JPWO2021067297A5 (fr) |